Science subjournal: mrna-lnp vaccine helps infants produce stronger immune response in the presence of maternal antibodies

January 19, 2020 / Biovalley BIOON / - -- babies are vulnerable to many infections A promising strategy to protect them is to vaccinate the mother during pregnancy, thus providing maternal antibodies that temporarily protect the baby from disease However, although maternal antibodies can provide short-term protection against a variety of infections for infants, they can also prevent infection or vaccination from generating antibody responses in infants from the beginning, resulting in increased long-term susceptibility of infants to infectious diseases Therefore, people need to develop vaccines that can induce protective immune response in the presence of antigen-specific maternal antibodies In a new study, researchers from the Perelman School of medicine at the University of Pennsylvania in the United States used a mouse model to confirm that influenza virus specific maternal antibodies prevent anti-body reactions from emerging from scratch in mice infected with influenza virus or vaccinated with conventional influenza vaccine The related research results were published in the Journal of Science Translational Medicine on January 8, 2020 The title of the paper is "nucleus modified mRNA safety partially overcomes physical antibody infection of de novo immune responses in mice" The researchers found that a recently developed influenza vaccine, nucleoside modified mRNA (mrna-lnp) encapsulated in lipid nanoparticles, partially overcame the blocking effect of maternal antibodies Compared with the conventional influenza vaccine approved for use in humans, this mrna-lnp influenza vaccine has established a long-lived germinal center in mouse pups and triggered a stronger antibody response It can be seen that the vaccination of mrna-lnp may provide a promising strategy for the generation of strong immune responses in infants with maternal antibodies (BIOON Com) reference: Elinor Willis et al Nuclear modified mRNA validation partially overcomes physical anti infection infection of de novo immune responses in mice Science Translational Medicine, 2020, DOI: 10.1126/scitranslmed.aav5701